There goes another one: Cambridge, MA’s Archemix has withdrawn its planned IPO, citing unfavorable market conditions. The deal was to have been worth up to $63 million. VentureBeat Life Sciences has a good look at the quickly worsening environment for biotech offerings, in case you’re not bummed out enough already.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
